

List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse), 31.03.2018

Dated 9 January 2018

NOTIFICATION

Sopharma AD notifies that for December 2017 the Company recorded an increase of sales revenues of 21% compared to the same month of 2016, including 73% increase of domestic sales and 4% increase of export sales.

For 2017, revenues from sales increased by 13% compared to 2016, including 3% increase of domestic sales and a 20% increase of export sales.

Dated 11 January 2018

NOTIFICATION

Sopharma AD plans to build the new lyophilic factory in Sofia in the first half of 2018. With the construction of the plant Sopharma AD will double the capacity of its current production facilities, which will ensure the production of sufficient quantities of the life-saving hospital product Methylprednisolone and will create additional workplaces. The built-up area will be about 3000 square meters, the building is planned to be two-storey and include both production and service spaces which are of particular importance for this highest-grade production because they provide the necessary purified water, humidity, purity, temperature and air pressure in the internal production environment, purified steam, etc. The whole project is expected to cost around 30 million leva.

Dated 30 January 2018

NOTIFICATION

Publication of the individual quarterly report for the fourth quarter of 2017 of Sopharma AD.

Dated 30 January 2018

NOTIFICATION

Sopharma AD received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.

The date of the registration of the transaction with the Central Depository is 24 January 2018.

Dated 30 January 2018

NOTIFICATION

Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.

During this successful year, the company took two important investment decisions, namely to start the construction of:

1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and

2. A new lyophilic plant in Sofia, a necessary step for increasing the production capacity for the life-saving Methylprednisolone.

After nearly five years of low investment activity these projects are a logical continuation of the company's sustainable development program and our well-recognized social function in the healthcare sector in Bulgaria.

Dated 5 February 2018

NOTIFICATION

Sopharma AD notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.

Dated 8 February 2018

NOTIFICATION

Sopharma AD notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.

Dated 23 February 2018

NOTIFICATION

Sopharma AD notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place.

The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession.

The General meeting of shareholders approved the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger").

The General meeting of shareholders approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved changes in the Company's Articles of Association which allows the payment of an interim dividend on the basis of a 6-month financial statement under the Public Offering of Securities Act.

The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approved a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition - no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share;

The minutes of the General Meeting of Shareholders of Sopharma AD, held on 23.02.2018, will be sent to you within the statutory term. All conversion documents are available as part of the materials of the extraordinary general meeting.

Dated 23 February 2018

NOTIFICATION

Publishing the Minutes of the EGMS, held on 23.02.2018.

Dated 1 March 2018

NOTIFICATION

Publication of quarterly consolidated statement for the fourth quarter of 2017 of Sopharma Group.

Dated 1 March 2018

NOTIFICATION

Sopharma Group reported for the first time over BGN 1 billion in sales revenue for 2017, marking an increase of 15.9%. Over the same period, the Group achieved a 25.4% increase in operating profit, a 17.5% increase in EBITDA. Net profit declined by 16.1% due to the lack of one-off transactions that resulted in extremely high financial revenues as they were in 2016.

In the past year, a number of companies joined the Group, including Lekovit, Serbia and the pharmacies chain PharmaStore, Bulgaria. There is a process of integration of both structures and the achievement of synergy in all directions of the activity.

Dated 6 March 2018

NOTIFICATION

Sopharma AD notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.

For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.

Dated 30 March 2018

NOTIFICATION

Publication of the Annual Individual Report of Sopharma AD as at 31.12.2017.